CDC: Effectiveness of flu vaccine in seniors only 9%
ATLANTA — This year’s triumvirate influenza vaccine was less effective in seniors as compared to the general population, according to the Centers for Disease Control and Prevention’s "Morbidity and Mortality Weekly Report" published Friday. Overall effectiveness of the vaccine was 56%, similar to an earlier interim estimate of 62%.
The adjusted, age-stratified vaccine effectiveness point estimates were 58% for children, 46% for adults younger than 50, 50% for men and women between the ages of 50 years and 64 years and 9% for seniors.
"These adjusted vaccine effectiveness estimates indicate that vaccination with the 2012–13 influenza season vaccine reduced the risk for outpatient medical visits resulting from influenza by approximately one half to two thirds for most persons, although [effectiveness] was lower and not statistically significant among older adults," the report read.
For the complete Feb. 22 MMWR issue, click here.
Rise-N-Shine highlights Wake Up on Time energy supplement
SPARTA TOWNSHIP, N.J. — Rise-N-Shine recently highlighted its Wake Up on Time supplement formulated to help night owls transform into morning people. Taken right before bed, Wake Up on Time starts to work six to eight hours later by releasing energy supplements for an alert, refreshed feeling.
“It’s more than a vitamin; it’s time in a bottle because, instead of hitting the snooze button over and over again, our product allows you bounce out of bed, ready to go,” Cathy Beggan, founder of Rise-N-Shine stated.
Wake Up On Time is a proprietary blend of B vitamins, amino acids, guarana seed extract and siberian ginseng that are geared to address the psychological and physical reasons why people have trouble getting out of bed in the morning.
Study: Smoking cessation and reduced tobacco intake compels ‘non-quitters’ to quit
ROCHESTER, Minn. — Smokeless tobacco users who said they didn’t want to quit changed their minds or significantly cut back when given nicotine lozenges or tobacco-free snuff in a Mayo Clinic study.
The findings are published in the February issue of Addictive Behaviors.
Mayo researchers recruited 81 users of chewing tobacco or snuff with no intention of quitting in the next 30 days. Forty were given 4-mg nicotine lozenges and 41 received tobacco-free snuff to help cut back their smokeless tobacco use. They were asked to cut back 50% by one month and 75% by two months.
Participants received eight weeks of treatment and behavioral counseling on tobacco reduction strategies with follow-up to 26 weeks. Both groups significantly reduced smokeless tobacco use in cans used per week and dips per day and sustained it through the end of the study. About one-third of study participants continued using 75% less smokeless tobacco use 26 weeks after the study, and 12% of the participants quit using it completely.
“The reason why that is so striking and important to us is these patients had no intention of quitting,” stated addiction expert Jon Ebbert, a tobacco researcher at the Mayo Clinic Nicotine Dependence Center. “Through the process of just reducing their tobacco, participants wanted to quit and were successful in doing so.”
The study was funded by the National Cancer Institute.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.